ROVI has renewed its ‘Excellent’ rating in the Profarma 2021-2022 Programme for Promoting Competitiveness in the pharmaceutical industry, awarded by the Ministry of Industry, Trade and Tourism.
This programme classifies and rates companies in a series of groups and categories (Excellent, Very Good, Good and Acceptable) according to their excellence in different industrial, economic and research, development and innovation aspects.
The aim is to favour the competitiveness of the sector by boosting activities that provide greater added value, such as investment in new plants and new production technologies, promoting R&D&I.